To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide
(Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with
relapsing forms of MS
To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability
progression, MRI lesions, cognitive performance and quality of life To evaluate the safety
and tolerability of daily SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168
and relevant metabolites and its relationship to efficacy and safety To evaluate
pharmacodynamics (PD) of SAR442168
Study duration will vary per participant in this event driven trial with a treatment duration
of approximately 18 to 36 months. Participants completing the study will be offered to
participate in a long term safety study.
Relapsing Multiple Sclerosis
Placebo to match SAR442168,
Placebo to match Teriflunomide,
Placebo to match Tolebrutinib
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.